88 related articles for article (PubMed ID: 1970776)
1. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
Karim A; Kook C; Novotney RL; Zagarella J; Campion J
Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
[TBL] [Abstract][Full Text] [Related]
4. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
Cook CS; Karim A; Sollman P
Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
Takahashi H; Tamura A; Ogata H; Masuhara K
J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of a disopyramide metabolite in renal failure.
Inagaki Y; Amano I; Otsu T
ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
[TBL] [Abstract][Full Text] [Related]
10. Human pharmacokinetics and metabolism of disopyramide enantiomers.
Le Corre P; Gibassier D; Sado P; Le Verge R
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Aitio ML; Allonen H; Kanto J; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
[TBL] [Abstract][Full Text] [Related]
12. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
[TBL] [Abstract][Full Text] [Related]
13. [Accumulation of a disopyramide metabolite in renal failure].
Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
[TBL] [Abstract][Full Text] [Related]
14. Interspecies differences in enantioselective mono-N-dealkylation of disopyramide by human and mouse liver microsomes.
Echizen H; Mochizuki K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1994 Mar; 268(3):1518-25. PubMed ID: 8138963
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of disopyramide and its mono-N-dealkylated metabolite in conscious dogs with chronic atrioventricular block: plasma concentration-response relationships.
Dubray C; Boucher M; Paire M; Pinatel H; Duchêne-Marullaz P
J Cardiovasc Pharmacol; 1986; 8(6):1229-34. PubMed ID: 2434751
[TBL] [Abstract][Full Text] [Related]
16. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes.
Echizen H; Kawasaki H; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1993 Mar; 264(3):1425-31. PubMed ID: 8450476
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
Aso R; Ohashi K; Katoh T; Ogata H
Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143
[TBL] [Abstract][Full Text] [Related]
18. In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data.
Le Corre P; Ratanasavanh D; Chevanne F; Gibassier D; Sado P; Le Verge R; Guillouzo A
Chirality; 1991; 3(5):405-11. PubMed ID: 1756095
[TBL] [Abstract][Full Text] [Related]
19. Frequency and voltage-dependent effects of mono-N-dealkyldisopyramide, the major metabolite of disopyramide, in canine ventricular tissue.
Toy W; Sasyniuk BI
J Pharmacol Exp Ther; 1990 Aug; 254(2):603-11. PubMed ID: 2166798
[TBL] [Abstract][Full Text] [Related]
20. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Pike E; Lunde PK
Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
